A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Public ClinicalTrials.gov record NCT03790111. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin \[cis\] plus gemcitabine \[gem\])
Study identification
- NCT ID
- NCT03790111
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 12, 2019
- Primary completion
- Jan 12, 2022
- Completion
- Jan 12, 2022
- Last update posted
- Apr 18, 2023
2019 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TerSera Investigational Site | Gilbert | Arizona | 85234 | — |
| TerSera Investigational Site | Fullerton | California | 92835 | — |
| TerSera Investigational Site | Gainesville | Florida | 32610 | — |
| TerSera Investigational Site | Tampa | Florida | 33612 | — |
| TerSera Investigational Site | Chicago | Illinois | 60637 | — |
| TerSera Investigational Site | Westwood | Kansas | 66205 | — |
| TerSera Investigational Site | Lexington | Kentucky | 40536 | — |
| TerSera Investigational Site | Boston | Massachusetts | 02118 | — |
| TerSera Investigational Site | Grand Rapids | Michigan | 49503 | — |
| TerSera Investigational Site | Buffalo | New York | 14263 | — |
| TerSera Investigational Site | Lake Success | New York | 11042 | — |
| TerSera Investigational Site | Charlotte | North Carolina | 28204 | — |
| TerSera Investigational Site | Oklahoma City | Oklahoma | 73104 | — |
| TerSera Investigational Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03790111, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 18, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03790111 live on ClinicalTrials.gov.